



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	104.06
Trade Time:	2:21 PM ET Nov 17, 2017
Change:	0.71 (0.687%)
Day Range	103.24 - 104.59
52-Week Range	94.55 - 147.17
Volume	3,804,786

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Nov 16, 2017
[Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma](#)

Nov 1, 2017
[Celgene Prices \\$3 Billion of Senior Unsecured Notes](#)

Oct 31, 2017
[Celgene Announces Offering of Senior Unsecured Notes](#)

Oct 28, 2017
[Efficacy and Safety Results from Second Phase III Trial \(RADIANCE™ Part B\) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting](#)

Oct 27, 2017
[Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod \(SUNBEAM™\) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting](#)

Upcoming Events [\[View all \]](#)

Nov 30, 2017 11:00 AM ET
[Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 10, 2017
[Annual Report \(10-K\)](#)

Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)

Oct 26, 2017
[Quarterly Report \(10-Q\)](#)

Jul 27, 2017
[Quarterly Report \(10-Q\)](#)

Apr 27, 2017
[Quarterly Report \(10-Q\)](#)

